- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00852566
Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)
An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
An Open-Label, Randomized, Multicenter Phase II Trial Comparing the depletion of malignant stem cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Estimated Number of Study Centers and Countries/Regions: Appr. 12 sites in 5 Nordic countries. Stem cell analyses will be performed in 4 Nordic centers (Helsinki, Lund, Oslo and Stockholm).
Study Phase: II
Research Hypothesis: Treatment with dasatinib 100 mg daily (QD) results in greater and more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy than imatinib 400 mg QD in newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients.
Primary Objective: To compare the number of Ph-positive cells in the stem cell compartment in newly diagnosed CP CML patients treated with dasatinib 100 mg QD vs. imatinib 400 mg QD.
Study Design: open-label randomized Phase II trial in newly diagnosed CML patients in CP. Patients will be randomized to receive dasatinib at a starting dose of 100 mg QD or imatinib at a starting dose of 400 mg QD.
Duration of Study: The study will be open for enrollment until the planned number of 40 patients is randomized. All patients will be treated and/or followed for up to 18 months. Based on the amendment 1 (Oct 2011), the follow-up of the patients will continue additional 4 years until 31.12.2015.
Number of Patients per Group: Approximately 40 patients will be randomized, 20 patients to dasatinib and 20 to imatinib. Additional patients will be recruited in case insufficient amount of representative samples have been obtained from first 40 patients.
Study Population: Patients 18 years or older with a newly diagnosed CP CML, not previously treated with any systemic treatments for CML
Study Assessments and Endpoints:
All stem cell assays are based on the preselection of CD34+ cells from large volume of bone marrow (BM) aspirates using paramagnetic beads. The CD34+ fraction will be further subdivided based on the expression of CD38 marker (positive vs. negative) using a sorting flow cytometer.
The primary endpoint is a comparison of proportion of Ph-positive cells in stem cell compartments (CD34+CD38neg and CD34+CD38+) at 6 months between the study arms.
Secondary endpoints are comparisons between treatment arms for: (1) the number of Ph-positive cells in all stem cell compartments at 1 and 3 months, (2) BCR-ABL RQ-PCR in blood at 1, 3, 6, 12 and 18 months, and (3) rate of CCyR within 3, 6, 12 and 18 months.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Helsinki, Finlandia, 00029
- Helsinki University Central Hospital
-
-
-
-
-
Bergen, Norvegia
- Bergen University Central Hospital
-
Oslo, Norvegia, 0027
- Rikshospitalet
-
Trondheim, Norvegia, 7006
- St. Olavs Hospital
-
-
-
-
-
Lund, Svezia, 22185
- Lund University Hospital
-
Stockholm, Svezia, 17176
- Karolinska University Hospital
-
Uppsala, Svezia, 75185
- Uppsala University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients are able to provide written informed consent
Patients must have CML in CP which is defined by the presence of all of the following criteria:
- < 15% blasts in peripheral blood (PB) and BM.
- < 30% blasts plus promyelocytes in PB and BM.
- < 20% basophils in the PB.
- ≥ 100 x 109/L platelets.
- No evidence of extramedullary leukemia apart from hepatosplenomegaly
- Ph+ or variants must be demonstrated by BM cytogenetics, FISH or PCR.
- Previously untreated CML in CP, with the exception of hydroxyurea or anagrelide
- Patients must be enrolled in this study within 90 days after the date of first being diagnosed with CML
- ECOG Performance Status (PS) Score 0 - 1 (see Appendix 2)
- Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional upper limit of normal (ULN) in absence of Gilbert type unconjugated hyperbilirubinemia; alanine aminotransferase (ALAT≤ 2.5 times the institutional ULN.
- Adequate renal function defined as serum creatinine ≤ 2 times the institutional ULN.
- Men and women, ages 18 years and older.
- Adequate BM aspiration sample before the start of study treatment (i.e sample is sufficient for stem cell analysis)
- Potentially fertile women must use an adequate method of contraception to avoid pregnancy throughout the study.
- Potentially fertile women must have a negative serum or urine pregnancy test
Exclusion Criteria:
- Fertile women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study
- Women who are pregnant or breastfeeding.
- Men with fertile sexual partners who can or will not use an acceptable contraception method for the entire study
- A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.
- Known pleural effusion at baseline.
- Uncontrolled or significant cardiovascular disease
- History of significant bleeding disorder unrelated to CML, including:
- Prior chemotherapy for peripheral stem cell mobilization.
- Inadequate BM aspiration sample due to marrow fibrosis or other reasons
- Prior or concurrent malignancy
- Severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent
- Abuse of alcohol, prescribed or illicit drugs
- Evidence of digestive dysfunction that would prevent administration of study therapy by mouth.
Prohibited Treatments and/or Therapies
- Any prior treatment with interferon
- Any prior treatment with dasatinib
- Any prior treatment with imatinib
- Any other prior systemic treatments, with anti-CML activity [except for anagrelide, or hydroxyurea (HU)].
- Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes as described in Appendix 3.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Imatinib
Standard treatment Imatinib 400mg OD
|
Per oral imatinib 400mg once daily (continuous medication)
Altri nomi:
|
Sperimentale: dasatinib
Dasatinib 100mg OD
|
Per oral dasatinib 100mg once daily (continuous medication)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Ph-positive cells in stem cell compartments
Lasso di tempo: 6 months
|
proportion of Ph-positive cells in stem cell compartments (CD34+CD38neg and CD34+CD38+)
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
BCR-ABL RQ-PCR in blood
Lasso di tempo: up to 18 months (1, 3, 6, 12 and 18 months)
|
up to 18 months (1, 3, 6, 12 and 18 months)
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Satu Mustjoki, MD, PhD, Helsinki University Central Hospital, Helsinki, Finland
- Cattedra di studio: Henrik Hjorth-Hansen, MD, PhD, St Olavs Hospital, Trondheim, Norway
- Cattedra di studio: Ole Weiss-Bjerrum, MD, PhD, Rigshospitalet, Denmark
- Cattedra di studio: Ingunn Dybedal, MD, PhD, Rikshospitalet, Oslo, Norway
- Cattedra di studio: Tobias Gedde-Dahl, MD, PhD, Rikshospitalet, Oslo, Norway
- Cattedra di studio: Kimmo Porkka, MD, PhD, Helsinki University Central Hospital, Helsinki, Finland
- Cattedra di studio: Johan Richter, MD, PhD, University of Lund, Lund, Sweden
- Cattedra di studio: Bengt Simonsson, MD, PhD, University Hospital, Uppsala, Sweden
- Cattedra di studio: Leif Stenke, MD, PhD, Karolinska Institutet
Pubblicazioni e link utili
Pubblicazioni generali
- Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Hoglund M, Koskenvesa P, Lotfi K, Majeed W, Markevarn B, Ohm L, Olsson-Stromberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13.
- Christiansson L, Soderlund S, Mangsbo S, Hjorth-Hansen H, Hoglund M, Markevarn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Stromberg U. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015 May;14(5):1181-91. doi: 10.1158/1535-7163.MCT-14-0849. Epub 2015 Mar 11.
- Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevarn B, Olofsson T, Olsson-Stromberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H; Nordic CML Study Group (NCMLSG). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 2013 Jul;27(7):1520-6. doi: 10.1038/leu.2013.19. Epub 2013 Jan 18.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Malattie del midollo osseo
- Malattie ematologiche
- Malattie mieloproliferative
- Leucemia
- Leucemia, mieloide
- Leucemia, Mielogena, Cronica, BCR-ABL Positivo
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della chinasi proteica
- Imatinib mesilato
- Dasatinib
Altri numeri di identificazione dello studio
- 2008-004106-13
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Imatinib
-
Scandinavian Sarcoma GroupCompletato
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletatoLeucemia mieloide cronicaCina
-
Novartis PharmaceuticalsCompletatoTumori stromali gastrointestinaliStati Uniti, Francia, Belgio, Germania
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoMelanoma | Neoplasie cutaneeStati Uniti
-
Seoul St. Mary's HospitalNovartisSconosciutoLeucemia mieloide cronicaCorea, Repubblica di
-
Novartis PharmaceuticalsTerminatoLeucemia MieloideStati Uniti, Germania, Belgio, Italia, Spagna, Corea, Repubblica di, Brasile, Giappone, Australia, Repubblica Ceca
-
Dr. Jurjan AmanExvastat Ltd.; Simbec-Orion Group; KABS laboratoriesTerminatoCovid19 | Disfunzione endoteliale | Sindrome da distress respiratorio acuto | Sindrome da distress respiratorio acuto | Edema polmonareOlanda
-
University of Auckland, New ZealandLeukaemia & Blood Cancer New ZealandAttivo, non reclutanteLeucemia mieloide cronicaNuova Zelanda
-
M.D. Anderson Cancer CenterJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletatoLeucemia, mieloide, cronicaStati Uniti
-
M.D. Anderson Cancer CenterNovartisCompletatoLeucemia Mieloide Acuta | Leucemia Mieloide Cronica | Metaplasia mieloide agnogenicaStati Uniti